Form 4: Pure Bioscience Director Acquires Stock Options

Director Ivan Chen acquired stock options in Pure Bioscience, Inc.

Summary

• On August 20, 2024, Ivan Chen, a director of Pure Bioscience, Inc., acquired stock options to purchase 150,000 shares of common stock at an exercise price of $0.07 per share.
• The options vest in two tranches: 50% on the earlier of January 15, 2025, or the date of the 2025 annual meeting, and the remaining 50% on the earlier of January 15, 2026, or the date of the 2026 annual meeting.
• Following the transaction, Mr. Chen beneficially owns 150,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to a director. While insider ownership can be a positive signal, this is just a grant, not an open market purchase.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. It's common for directors and officers to receive stock options as part of their compensation.

Stakeholder Impact

• The granting of stock options to a director could potentially align the director's interests with those of the shareholders.

Key Dates

Keywords

stock options, director, PURE, Pure Bioscience, beneficial ownership, Form 4